Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Merrimack Pharmaceuticals Inc.
DescriptionPegylated liposomal doxorubicin formulation targeting HER2
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase II/III
Standard IndicationBreast cancer
Indication DetailsTreat advanced HER2-positive breast cancer; Treat HER2-positive, locally advanced or metastatic breast cancer
Regulatory Designation
PartnerLigand Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today